Jan Hardorp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Ksana Health Secures $2M Seed Round to Launch Advanced Mental Health Monitoring Platform
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Meet the mobile therapy startup backed by Christian Angermayer s re:Mind Capital – TechCrunch
techcrunch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from techcrunch.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SALT LAKE CITY, May 19, 2021 /PRNewswire/ Blackrock Neurotech, the world s leading platform for brain-computer interface (BCI) technology and manufacturing, has closed a $10 million financing round, led by Christian Angermayer s re.Mind Capital with participation from Peter Thiel, German entrepreneur Tim Sievers, and Sorenson Impact s University Venture Fund II.
Christian Angermayer and Jan Hardorp of re.Mind, as well as Tim Sievers will join the Blackrock Neurotech Board of Directors. The funding will be used to further expand the number of programs on the Blackrock platform – including clinical studies and cutting-edge research – and to continue development of its technology platform to maintain a leading position in the market.
CB Therapeutics Inc., a Carlsbad, CA-based synthetic biology company focused on the development and biosynthetic production of existing and novel tryptamines and cannabinoids, closed a Series A funding round of undisclosed amount.
The round was filled entirely by re.Mind Capital, a fund launched by Christian Angermayer within Apeiron, his family office.
The company intends to use the funds to accelerate their scaled up manufacturing and sale of cannabinoids and tryptamines.
Led by Sher Ali Butt, CEO, and Dr. Jacob Vogan, CSO, CB Therapeutics is a biotechnology company that develops synthetic biology solutions to address mental health issues and increase healthspan. Its proprietary cellular agriculture platform enables next generation biosynthetic production of cannabinoids and psychedelic medicines and their analogs to further clinical research for various serious health conditions.